NeoGenomics highlighting advances in drug development strategies at recent clinical meetings

NeoGenomics is pleased to have attended meetings this year where we've had the opportunity to highlight advances in drug development strategies.

Read More

Women's Health and Fitness Day

September 27 is National Women's Health And Fitness Day. This annual observance strives to spread education about health and wellness, encourage women to prioritize their health, and more.

Read More

How does medical purpose drive regulatory requirements in EU clinical trials?

Clear and accurate assessment of whether use of an assay in a clinical trial assay is considered exploratory or an “IVD” is necessary as implications extend to quality/regulatory pathways, assay de

Read More

Taking Spatial Toward the Clinic: DeciBio’s Q&A with Sandy Au of NeoGenomics

Blog originally posted on Decibio Insights here.

Read More

Is IHC going to exhaust our archival blocks the way single gene testing used to?

Over the past year we have seen unprecedented demand for IHC assay development services with the goal of creating a prototype CDx assay.

Read More

Orphan CDx assays

Drug development is rapidly outpacing our ability to bring companion diagnostics to market.

Read More

First CDx Approval for HLA Typing

We have seen HLA typing become more prominent in oncology clinical studies. Especially in the realm of immuno-oncology therapeutics including CAR T-cells, bi-specifics, and cancer vaccines.

Read More

ISO 15189 accreditation of the Swiss and Singapore NeoGenomics sites

In 2020 NeoGenomics decided to launch an accreditation program for its international sites in Switzerland and Singapore.

Read More
Written By:
Charlotte Serra profile image
Charlotte Serra

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients